>PROKKA_00001 Botulinum neurotoxin type F precursor
MMPERYNNALNHYYRKEYYVIDYFKNYNINGFKNGQIKTKLPLSKYNKEIINKPELIVNL
INQNNTVLMKSNIYGDGLKGTVDNFYSNYIIPYNLNYEHSINYSYLDNVNIEEIEKIPPI
NDEDIYPYRKNADTFIPVYNITKAKEINTTTPLPVNYLQAQMIDSNDINLSSDFLKVISS
KGSLVYSFLNNTMDYLEFIKYDKPIDTDKKYYKWLKAIFRNYSLDITETQEISNQFGDTK
IIPWIGRALNILNTNNSFVEEFKNLGPISLINKKENITIPKIKIDEIPSSMLNFSFKDLS
ENLFNIYCKNNFYLKKIYYNFLDQWWTQYYSQYFDLICMASKSVLAQEKLIKKLIQKQLR
YLMENSNISSTNLILINLTTTNTLRDISNQSQIAINNIDKFFNNAAMCVFENNIYPKFTS
FMEQCIKNINKSTKEFILKCTNINETEKSHLIMQNSFSNLDFDFLDIQNMKNLFNSYTEL
LIKEQTSPYELSLYAFQEQDNNVIGDTSGKNTLVEYPKDIGLVYGINNNAIHLTGANQNI
KFTNDYFENGLTNNFSIYFWLRNLKQNTIKSKLIGSKEDNCGWEIYFENDGLVFNIIDSN
GNEKNIYLSNISNNSWHYIVISINRLKDQLLIFIDNILVANEDIKEILNIYSSDIISLLS
DNNNVYIEGLSVLNKTINSNEILTDYFSDLNNSYIRNFDEEILQYNRTYELFNYVFPEIA
INKIEQNNNIYLSINNENNLNFKPLKFKLLNTNPNKQYVQKWDEVIFSVLDGTEKYLDIS
TTNNRIQLVDNKNNAQIFIINNDIFISNCLTLTYNNVNVYLSIKNQDYNWVICDLNHDIP
KKSYLWILKNI*
>PROKKA_00002 Botulinum neurotoxin type E precursor
MPKINSFNYNDPVNDRTILYIKPGGCQEFYKSFNIMKNIWIIPERNVIGTTPQDFHPPTS
LKNGDSSYYDPNYLQSDEEKDRFLKIVTKIFNRINNNLSGGILLEELSKANPYLGNDNTP
DNQFHIGDASAVEIKFSNGSQHILLPNVIIMGAEPDLFETNSSNISLRNNYMPSNHGFGS
IAIVTFSPEYSFRFNDNSINEFIQDPALTLMHELIHSLHGLYGAKGITTTCIITQQQNPL
ITNRKGINIEEFLTFGGNDLNIITVAQYNDIYTNLLNDYRKIASKLSKVQVSNPQLNPYK
DIFQEKYGLDKDASGIYSVNINKFDDILKKLYSFTEFDLATKFQVKCRETYIGQYKYFKL
SNLLNDSIYNISEGYNINNLKVNFRGQNANLNPRIIKPITGRGLVKKIIRFCKNIVSVKG
IRKSICIEINNGELFFVASENSYNDDNINTPKEIDDTVTSNNNYENDLDQVILNFNSESA
PGLSDEKLNLTIQNDAYIPKYDSNGTSDIEQHDVNELNVFFYLDAQKVPEGENNVNLTSS
IDTALLEQPKIYTFFSSEFINNVNKPVQAALFVSWIQQVLVDFTTEANQKSTVDKIADIS
IVVPYIGLALNIGNEAQKGNFKDALELLGAGILLEFEPELLIPTILVFTIKSFLGSSDNK
NKVIKAINNALKERDEKWKEVYSFIVSNWMTKINTQFNKRKEQMYQALQNQVNAIKTIIE
SKYNSYTLEEKNELTNKYDIKQIENELNQKVSIAMNNIDRFLTESSISYLMKLINEVKIN
KLREYDENVKTYLLNYIIQHGSILGESQQELNSMVTDTLNNSIPFKLSSYTDDKILISYF
NKFFKRIKSSSVLNMRYKNDKYVDTSGYDSNININGDVYKYPTNKNQFGIYNDKLSEVNI
SQNDYIIYDNKYKNFSISFWVRIPNYDNKIVNVNNEYTIINCMRDNNSGWKVSLNHNEII
WTLQDNAGINQKLAFNYGNANGISDYINKWIFVTITNDRLGDSKLYINGNLIDQKSILNL
GNIHVSDNILFKIVNCSYTRYIGIRYFNIFDKELDETEIQTLYSNEPNTNILKDFWGNYL
LYDKEYYLLNVLKPNNFIDRRKDSTLSINNIRSTILLANRLYSGIKVKIQRVNNSSTNDN
LVRKNDQVYINFVASKTHLFPLYADTATTNKEKTIKISSSGNRFNQVVVMNSVGNNCTMN
FKNNNGNNIGLLGFKADTVVASTWYYTHMRDHTNSNGCFWNFISEEHGWQEK*
>PROKKA_00003 Helix-turn-helix domain protein
MNRNIIGKKVRIIRKLKNLTQEELIAIIQLKCLSIDRPMLSRIETDSREVYDFEVKAIAE
ALDISVDELFIQN*
>PROKKA_00004 Replication-associated recombination protein A
MTPLAERMRPTKLEDFVGQKQIIGEGKPLYNIIKSKNIVNCILYGPPGTGKTTLANIMAN
YVDRKFYKLNATTASVKDIQEIASSLDTLLGYNGVVVYIDELQHFSKKQQQSLLEFIEKG
QITLIASTTENPYFVLHKAILSRCNIFTFKPLTTDDIKFGVVKAIERAIENGMEIKYTDD
AISYIAEISQGDYRKAYNILELGIISSLKRTLEITAEYIEELEQSHIRFDASGDEFYNSL
SALQKSIRGSDVDAAIHYLARLIKSGNLTAIVRRLGVIVAEDIGLAHPNALTVVNSGLEL
VLKVGLPEAQLILSELVIYLATLPKSNSAYLAIKSAMQDLENKNVGDVPMHLKDAHYSGA
QKLGVGGYKYPHDYSNNYVKQQYMPQELRDTIYYIPQENKYEGSIKNYWKNIKE*
>PROKKA_00005 hypothetical protein
MGKAGRKENCNISDNDMLVALERYTREFPNEKINIKKLADFSGIERHYWYSRKGLREKIE
EINSISYEKYDIISDGDRKKIKFPNVDEVVDNNFRNKKRLKFILNSFFLTYQDFYESSCE
AYKLKKDINILKDKIIKYEDEIQKLKNERDKFRELSNYNENKYYEIAIRSRERNFRKENN
IKSNVIEINNKNIKAYSTDEDDLDSLLNRIDD*
>PROKKA_00006 hypothetical protein
LINLLINLININTIVERVRVVSDIINISNFFDIDKFNEFEEYIESTFDNNKLNMKDYTMN
FISFIRDNVDEEYCNYLVSLPNEYFSKTREIPDYTSILKFDFLLDKYLKNSDEKEFFRYY
PIVLWWKICSKIPLRPCEFMILKKDCVYEKNRKYYIRIRRCKPHGFVNKALNIRKEQSFR
INKEIYDLVMKVVSHKSHDCEFLLSKNLYNKYYTQYTYKEELVQGRVMRSYNLDKCLKDF
YYYEINNKNIQTVISKKDVKESLSQQFYRDCMVSLQLGDARHLAIINLVLQGTNSYLIRE
MCGHRDINSHLHYIDHAKTYITSKVLVLTDIRKLEIKLANIYSNESFEYGNKRNNKVSNL
LYNEYKKVGDIYCKRYVGREEMFPFLCLTDCDECNDKVETDFTGNNDEEIKINKMEIERQ
FQIIEKYLKDAQFNSIIDSKNERVLFDSQKNIEESANKLNYLISKEAELEAKIFFGGIIT
KEE*
